Prognostic significance of geriatric assessment in combination with laboratory parameters in elderly patients with aggressive non-Hodgkin lymphoma

References

• Balducci L, Extermann M. Cancer and aging. An evolving panorama. Hematol Oncol Clin North Am 2000;14:1–16.
   PubMed Web of Science ®Google Scholar
• Nederlandse Kankerregistratie. Cifjers Over Kanker. 2014. Available from: www.cijfersoverkanker.nl.
   Google Scholar
• Howlader N, Noone AM, Krapcho M, et al., editors. SEER Cancer Statistics Review, 1975–2009 (vintage 2009 populations). Bethesda, MD: National Cancer Institute; 2011 (based on November 2011 SEER data submission, posted to the SEER web site, 2012). Available from: seer.cancer.gov/csr/
   Google Scholar
• Howlader N, Noone AM, Krapcho M, et al., editors. SEER Cancer Statistics Review, 1975–2011. Bethesda, MD: National Cancer Institute; 2013 (based on November 2013 SEER data submission, posted to the SEER web site, April 2014). Available from: http://seer.cancer.gov/csr/1975_2011/
   Google Scholar
• Curado MP, Edwards B, Shin HR. Cancer incidence in five continents, Vol IX. IARC Scientific Publication No. 160. 2008. Available from: www.iarc.fr
   Google Scholar
• Groves FD, Linet MS, Travis LB, et al. Cancer surveillance series: non-Hodgkin's lymphoma incidence by histologic subtype in the United States from 1978 through 1995. J Natl Cancer Inst 2000;92: 1240–1251.
   PubMed Web of Science ®Google Scholar
• Fisher RI, Gaynor ER, Dahlberg S, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 1993;328: 1002–1006.
   PubMed Web of Science ®Google Scholar
• Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002;346:235–242.
   PubMed Web of Science ®Google Scholar
• Peyrade F, Jardin F, Thieblemont C, et al. Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial. Lancet Oncol 2011;12:460–468.
   PubMed Web of Science ®Google Scholar
• Garman KS, Pieper CF, Seo P, et al. Function in elderly cancer survivors depends on comorbidities. J Gerontol A Biol Sci Med Sci 2003;58:M1119–M1124.
   PubMed Web of Science ®Google Scholar
• Shipp MA, Harrington DP, Anderson JR. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993;329:987–994.
   PubMed Web of Science ®Google Scholar
• Extermann M, Hurria A. Comprehensive geriatric assessment for older patients with cancer. J Clin Oncol 2007;25:1824–1831.
   PubMed Web of Science ®Google Scholar
• Extermann M, Overcash J, Lyman G. Comorbidity and functional status are independent in older cancer patients. J Clin Oncol 1998;16:1582–1587.
   PubMed Web of Science ®Google Scholar
• Repetto L, Fratino L, Audisio RA, et al. Comprehensive geriatric assessment adds information to Eastern Cooperative Oncology Group performance status in elderly cancer patients: an Italian Group for Geriatric Oncology Study. J Clin Oncol 2002;20:494–502.
   PubMed Web of Science ®Google Scholar
• Spina M, Balzarotti M, Uziel L, et al. Modulated chemotherapy according to modified comprehensive geriatric assessment in 100 consecutive elderly patients with diffuse large B-cell lymphoma. Oncologist 2012;17:838–846.
   PubMed Web of Science ®Google Scholar
• Soubeyran P, Fonck M, Blanc-Bisson C, et al. Predictors of early death risk in older patients treated with first-line chemotherapy for cancer. J Clin Oncol 2011;30:1829–1834.
   Web of Science ®Google Scholar
• Olivieri A, Gini G, Bocci C, et al. Tailored therapy in an unselected population of 91 elderly patients with DLBCL prospectively evaluated using a simplified CGA. Oncologist 2012;17:663–672.
   PubMed Web of Science ®Google Scholar
• Winkelmann N, Petersen I, Kiehntopf M, et al. Results of comprehensive geriatric assessment effect survival in patients with malignant lymphoma. J Cancer Res Clin Oncol 2011;137:733–738.
   PubMed Web of Science ®Google Scholar
• Trebouet A, Marchand T, Lemal R, et al. Lymphoma occurring in patients over 90 years of age: characteristics, outcomes, and prognostic factors. A retrospective analysis of 234 cases from the LYSA. Ann Oncol 2013;24:2612–2618.
   Google Scholar
• Ganti AK, Weisenburger DD, Smith LM, et al. Patients with grade 3 follicular lymphoma have prolonged relapse-free survival following anthracycline-based chemotherapy: the Nebraska Lymphoma Study Group Experience. Ann Oncol 2006;17:920–927.
   PubMed Web of Science ®Google Scholar
• Overman MJ, Feng L, Pro B, et al. The addition of rituximab to CHOP chemotherapy improves overall and failure-free survival for follicular grade 3 lymphoma. Ann Oncol 2008;19:553–559.
   PubMed Web of Science ®Google Scholar
• Aaldriks AA, Maartense E, le Cessie S, et al. Predictive value of geriatric assessment for patients older than 70 years, treated with chemotherapy. Crit Rev Oncol Hematol 2011;79:205–212.
   PubMed Web of Science ®Google Scholar
• Guigoz Y, Vellas B. The Mini Nutritional Assessment (MNA) for grading the nutritional state of elderly patients: presentation of the MNA, history and validation. Nestle Nutr Workshop Ser Clin Perform Programme 1999;1:3–11; discussion 11–12.
   PubMedGoogle Scholar
• Slaets JP. Vulnerability in the elderly: frailty. Med Clin North Am 2006;90:593–601.
   PubMed Web of Science ®Google Scholar
• Jorm AF, Jacomb PA. The Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE): socio-demographic correlates, reliability, validity and some norms. Psychol Med 1989; 19:1015–1022.
   PubMed Web of Science ®Google Scholar
• Folstein MF, Folstein SE, McHugh PR.“Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189–198.
   PubMed Web of Science ®Google Scholar
• Guigoz Y, Lauque S, Vellas BJ. Identifying the elderly at risk for malnutrition. The Mini Nutritional Assessment. Clin Geriatr Med 2002;18:737–757.
   PubMed Web of Science ®Google Scholar
• de Jonghe JF. Differentiating between demented and psychiatric patients with the Dutch version of the IQCODE. Int J Geriatr Psychiatry 1997;12:462–465.
   PubMed Web of Science ®Google Scholar
• Hodkinson HM. Evaluation of a mental test score for assessment of mental impairment in the elderly. Age Ageing 1972;1:233–238.
   PubMedGoogle Scholar
• Blanc-Bisson C, Fonck M, Rainfray M, et al. Undernutrition in elderly patients with cancer: target for diagnosis and intervention. Crit Rev Oncol Hematol 2008;67:243–254.
   PubMed Web of Science ®Google Scholar
• Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373–383.
   PubMedGoogle Scholar
• Karnofsky DA, Burchenal JH. The clinical evaluation of chemotherapeutic agents in cancer. In: MacLeod CM, editor. Evaluation of chemotherapeutic agents. New York: Columbia University Press; 1949. p 196.
   Google Scholar
• Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5:649–655.
   PubMed Web of Science ®Google Scholar
• European Organisation for Research and Treatment of Cancer (EORTC). 2010. Available from: http://www.eortc.be/services/doc/ctc/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf
   Google Scholar
• Carbone PP, Kaplan HS, Musshoff K, et al. Report of the Committee on Hodgkin's Disease Staging Classification. Cancer Res 1971;31:1860–1861.
   PubMed Web of Science ®Google Scholar
• Schuurmans H, Steverink N, Lindenberg S, et al. Old or frail: what tells us more? J Gerontol A Biol Sci Med Sci 2004;59:M962–M965.
   PubMed Web of Science ®Google Scholar
• Nabhan C, Smith SM, Helenowski I, et al. Analysis of very elderly (≥ 80 years) non-hodgkin lymphoma: impact of functional status and co-morbidities on outcome. Br J Haematol 2011;156:196–204.
   PubMed Web of Science ®Google Scholar
• Tucci A, Ferrari S, Bottelli C, et al. A comprehensive geriatric assessment is more effective than clinical judgment to identify elderly diffuse large cell lymphoma patients who benefit from aggressive therapy. Cancer 2009;115:4547–4553.
   PubMed Web of Science ®Google Scholar
• Extermann M, Boler I, Reich RR, et al. Predicting the risk of chemotherapy toxicity in older patients: the Chemotherapy Risk Assessment Scale for High-Age Patients (CRASH) score. Cancer 2012;118:3377–3386.
   PubMed Web of Science ®Google Scholar
• Hurria A, Togawa K, Mohile SG, et al. Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study. J Clin Oncol 2011;29:3457–3465.
   PubMed Web of Science ®Google Scholar
• Hoppe S, Rainfray M, Fonck M, et al. Functional decline in older patients with cancer receiving first-line chemotherapy. J Clin Oncol 2013;31:3877–3882.
   PubMed Web of Science ®Google Scholar
• Federico M, Bellei M, Marcheselli L, et al. Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. J Clin Oncol 2009;27:4555–4562.
   PubMed Web of Science ®Google Scholar
• Solal-Celigny P, Roy P, Colombat P, et al. Follicular lymphoma international prognostic index. Blood 2004;104:1258–1265.
   PubMed Web of Science ®Google Scholar
• Boslooper K, Kibbelaar R, Storm H, et al. Treatment with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone is beneficial but toxic in very elderly patients with diffuse large B-cell lymphoma: a population-based cohort study on treatment, toxicity and outcome. Leuk Lymphoma 2014;55:526–532.
   PubMed Web of Science ®Google Scholar
• Salles G, de Jong D, Xie W, et al. Prognostic significance of immunohistochemical biomarkers in diffuse large B-cell lymphoma: a study from the Lunenburg Lymphoma Biomarker Consortium. Blood 2011;117:7070–7078.
   PubMed Web of Science ®Google Scholar
• Sehn LH, Berry B, Chhanabhai M, et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood 2007;109:1857–1861.
   PubMed Web of Science ®Google Scholar
• Advani RH, Chen H, Habermann TM, et al. Comparison of conventional prognostic indices in patients older than 60 years with diffuse large B-cell lymphoma treated with R-CHOP in the US Intergroup Study (ECOG 4494, CALGB 9793): consideration of age greater than 70 years in an elderly prognostic index (E-IPI). Br J Haematol 2010;151:143–151.
   PubMed Web of Science ®Google Scholar
• Ziepert M, Hasenclever D, Kuhnt E, et al. Standard International prognostic index remains a valid predictor of outcome for patients with aggressive CD20 + B-cell lymphoma in the rituximab era. J Clin Oncol 2010;28:2373–2380.
   PubMed Web of Science ®Google Scholar
• Bari A, Marcheselli L, Sacchi S, et al. Prognostic models for diffuse large B-cell lymphoma in the rituximab era: a never-ending story. Ann Oncol 2010;21:1486–1491.
   PubMed Web of Science ®Google Scholar
• Janssen-Heijnen ML, van Spronsen DJ, Lemmens VE, et al. A population-based study of severity of comorbidity among patients with non-Hodgkin's lymphoma: prognostic impact independent of International Prognostic Index. Br J Haematol 2005;129: 597–606.
   PubMed Web of Science ®Google Scholar
• Mora O, Zucca E. Management of elderly patients with hematological neoplasms. Ann Oncol 2007;18:i49–i53.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007;25:579–586.
   PubMed Web of Science ®Google Scholar